Dow vs Guangdong Huiyun Titanium Industry: why the prices moved differently

• ▼

  Citi downgrades Dow, slashes price target and 2027 profit forecast Citi cut Dow to Neutral from Buy, lowered its price target to $30 from $35, and reduced its 2027 earnings estimate to $1.21 from $1.83. The analyst said weak demand means even $100 oil won't lift polyethylene prices much, so Dow's profit recovery looks smaller and further away.

  This is the most recent and most concrete negative signal, directly cutting the earnings and price outlook that drive DOW's valuation.

• ▼

  Analysts trim Dow estimates ahead of October 22 earnings Ahead of Dow's October 22 earnings report, analysts lowered their profit estimates over the past month, and the stock fell 1% to $27.61, down 8.62% in a month. Lower expectations mean even a decent quarter may not be enough to lift the shares.

  Shows the market's expectations are falling into the key earnings event, a direct drag on DOW's price.

• ▲

  Univar expands distribution of Dow's SupraCare products across US and Canada Univar widened its agreement to distribute Dow's SupraCare polymers and specialty additives in the US and Canada, reaching more homecare and industrial cleaning customers. This is a real but modest boost to Dow's sales reach, though it doesn't fix the bigger problem of weak overall chemical demand.

  A concrete new demand-side positive for Dow, but small relative to the demand and pricing headwinds.

• ◆

  Dow screens as undervalued, but a peer looks cheaper One analysis said Dow is undervalued, worth about $38 a share based on cash flow, while another preferred LyondellBasell because it's cheaper and lost less money. The bull case rests on Dow's low price, but weak demand and high costs keep the discount in place.

  Captures the valuation debate that frames whether DOW is a bargain or a value trap, a key part of the big picture.

Based on 6 stories →

• ▼

  Canada tariffs hit Dow exports Canada's retaliatory tariffs on U.S. goods took effect September 8, hitting plastics and chemicals that include Dow products. This makes Dow's exports to Canada more expensive, likely reducing sales and pressuring profit.

  New trade barrier directly affecting Dow's sales and pricing power.

• ◆

  Dow weighs selling Sadara stake Dow is reportedly considering selling its 35% stake in the $20 billion Sadara joint venture with Saudi Aramco. A sale could bring cash but forfeit future recovery upside, and the headline $20 billion is not the current value of Dow's stake.

  Portfolio move with major cash and strategic implications for Dow's balance sheet.

• ▼

  Dow trims Q3 EBITDA outlook Dow cut its third-quarter EBITDA forecast to $1.5–1.6 billion, citing weaker polyethylene pricing in the Americas and soft construction and automotive demand. This signals near-term earnings pressure, though cost cuts and working-capital release offer some offset.

  Direct reduction in expected earnings, a key driver of stock value.

• ◆

  Debt paydown prioritized over buybacks Dow will use excess cash to reduce debt and does not expect share buybacks in 2026, keeping the $0.35 dividend as the main shareholder return. This strengthens the balance sheet but removes a potential stock support, and the dividend is half its former level.

  Capital allocation shift affects shareholder returns and financial risk.

Based on 6 stories →

• ▼

  RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

  This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

• ▼

  Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

  This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

• ▼

  Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

  This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

• ▲

  Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

  These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

Based on 6 stories →